BJDX

Bluejay Diagnostics, Inc. BJDX

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.2M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-2.32M

Quarter to Jun 30

Free cash flow

$-1.64M

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026
$259.3K total
ARMISTICE CAPITAL, LLC
$157.2KNew
HEIGHTS CAPITAL MANAGEMENT, INC
$42.5KNew
BOOTHBAY FUND MANAGEMENT, LLC
$32.6KNew
BANK OF AMERICA CORP /DE/
$12.4KNew
VANGUARD FIDUCIARY TRUST CO
$12.3KNew
Tower Research Capital LLC (TRC)
$2.3K+10.3%
L1 Global Manager Pty Ltd
$1440.0%
Caitong International Asset Management Co., Ltd
$1-66.7%
See all 8 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

ROIC

Q2 2026
EDGAR

Free Cash Flow

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/BJDX

Earnings Per Share

13fpro.ai/company/BJDX

Loading ratio trend…

BJDX key financials by period

Reported revenue, net income and operating margin by fiscal year, from Bluejay Diagnostics, Inc.'s annual filings on SEC EDGAR.

Bluejay Diagnostics, Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2022$249.0K$-9.3M—
Source: BJDX filings on SEC EDGAR →

BJDX insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About Bluejay Diagnostics, Inc. (BJDX): stock profile, AI score and financials

Bluejay Diagnostics, Inc. (BJDX) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. BJDX is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.2m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (Q2 2026), Bluejay Diagnostics, Inc. reports net income of $-2.3M, free cash flow of $-1.6M. Top institutional holders of BJDX by reported 13-F value include ARMISTICE CAPITAL, HEIGHTS CAPITAL MANAGEMENT, BOOTHBAY FUND MANAGEMENT, based on the most recent SEC filings. BJDX trades on the Nasdaq exchange and files with the SEC under CIK 1704287. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate BJDX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Bluejay Diagnostics, Inc. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1704287 →